Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1989 Aug;63(8):3376–3381. doi: 10.1128/jvi.63.8.3376-3381.1989

Antibody-dependent cellular cytotoxicity detects type- and strain-specific antigens among human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates.

K Ljunggren 1, G Biberfeld 1, M Jondal 1, E M Fenyö 1
PMCID: PMC250912  PMID: 2746734

Abstract

Human cell lines were infected with different strains of human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) as well as with a simian immunodeficiency virus SIVmac isolate and used as targets in an antibody-dependent cellular cytotoxicity (ADCC) assay. Sera from HIV-1- or HIV-2-infected subjects provided the antibody, and lymphocytes from normal donors provided the effector cells. About 60% of HIV-1 antibody-positive sera mediated ADCC when tested against any given HIV-1 isolate-infected target cell (human T-cell lymphotropic virus type IIIB, B40, A2587), and about 75% of HIV-2 antibody-positive sera mediated ADCC when tested against target cells infected with HIV-2 isolates (lymphadenopathy-associated virus type 2 and SBL-6669) or simian immunodeficiency virus from macaques. Within each type, individual sera showed different reactivity patterns, and the probability that a serum was ADCC positive was higher when it was tested against several strains. When the ADCC reactivity of sera against different strains was compared, diversity as detected by ADCC appeared to be greater among HIV-1 strains than among HIV-2 strains. For HIV-1, 54 to 67% of the sera gave concordant ADCC reactions, whereas for HIV-2 and SIVmac, 91% of the sera gave concordant results. Almost no strain-specific differences were seen between SBL-6669 and lymphadenopathy-associated virus type 2. As we determined previously, HIV-1 and HIV-2 did not cross-react in ADCC. The results indicated that HIV-1 and HIV-2 antibody-positive sera mediate both strain- and type-specific ADCC. HIV-2 antibody-positive sera seem to mediate ADCC with broader reactivity and to a higher frequency compared with HIV-1 antibody-positive sera.

Full text

PDF
3376

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert J., Bredberg U., Chiodi F., Böttiger B., Fenyö E. M., Norrby E., Biberfeld G. A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. AIDS Res Hum Retroviruses. 1987 Spring;3(1):3–10. doi: 10.1089/aid.1987.3.3. [DOI] [PubMed] [Google Scholar]
  2. Asjö B., Ivhed I., Gidlund M., Fuerstenberg S., Fenyö E. M., Nilsson K., Wigzell H. Susceptibility to infection by the human immunodeficiency virus (HIV) correlates with T4 expression in a parental monocytoid cell line and its subclones. Virology. 1987 Apr;157(2):359–365. doi: 10.1016/0042-6822(87)90278-9. [DOI] [PubMed] [Google Scholar]
  3. Asjö B., Morfeldt-Månson L., Albert J., Biberfeld G., Karlsson A., Lidman K., Fenyö E. M. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet. 1986 Sep 20;2(8508):660–662. [PubMed] [Google Scholar]
  4. Barré-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet-Brun F., Rouzioux C. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871. doi: 10.1126/science.6189183. [DOI] [PubMed] [Google Scholar]
  5. Blumberg R. S., Paradis T., Hartshorn K. L., Vogt M., Ho D. D., Hirsch M. S., Leban J., Sato V. L., Schooley R. T. Antibody-dependent cell-mediated cytotoxicity against cells infected with the human immunodeficiency virus. J Infect Dis. 1987 Dec;156(6):878–884. doi: 10.1093/infdis/156.6.878. [DOI] [PubMed] [Google Scholar]
  6. Brun-Vezinet F., Rey M. A., Katlama C., Girard P. M., Roulot D., Yeni P., Lenoble L., Clavel F., Alizon M., Gadelle S. Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet. 1987 Jan 17;1(8525):128–132. doi: 10.1016/s0140-6736(87)91967-2. [DOI] [PubMed] [Google Scholar]
  7. Brücker G., Brun-Vezinet F., Rosenheim M., Rey M. A., Katlama C., Gentilini M. HIV-2 infection in two homosexual men in France. Lancet. 1987 Jan 24;1(8526):223–223. doi: 10.1016/s0140-6736(87)90043-2. [DOI] [PubMed] [Google Scholar]
  8. Böttiger B., Ljunggren K., Karlsson A., Krohn K., Fenyö E. M., Jondal M., Biberfeld G. Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I. Clin Exp Immunol. 1988 Sep;73(3):339–342. [PMC free article] [PubMed] [Google Scholar]
  9. Chiodi F., Bredberg-Råden U., Biberfeld G., Böttiger B., Albert J., Asjö B., Fenyö E. M., Norrby E. Radioimmunoprecipitation and Western blotting with sera of human immunodeficiency virus infected patients: a comparative study. AIDS Res Hum Retroviruses. 1987 Summer;3(2):165–176. doi: 10.1089/aid.1987.3.165. [DOI] [PubMed] [Google Scholar]
  10. Clavel F., Guétard D., Brun-Vézinet F., Chamaret S., Rey M. A., Santos-Ferreira M. O., Laurent A. G., Dauguet C., Katlama C., Rouzioux C. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986 Jul 18;233(4761):343–346. doi: 10.1126/science.2425430. [DOI] [PubMed] [Google Scholar]
  11. Clavel F., Mansinho K., Chamaret S., Guetard D., Favier V., Nina J., Santos-Ferreira M. O., Champalimaud J. L., Montagnier L. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med. 1987 May 7;316(19):1180–1185. doi: 10.1056/NEJM198705073161903. [DOI] [PubMed] [Google Scholar]
  12. Goudsmit J., Debouck C., Meloen R. H., Smit L., Bakker M., Asher D. M., Wolff A. V., Gibbs C. J., Jr, Gajdusek D. C. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478–4482. doi: 10.1073/pnas.85.12.4478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goudsmit J., Ljunggren K., Smit L., Jondal M., Fenyö E. M., Jonda M. Biological significance of the antibody response to HIV antigens expressed on the cell surface. Arch Virol. 1988;103(3-4):189–206. doi: 10.1007/BF01311092. [DOI] [PubMed] [Google Scholar]
  14. Goudsmit J., Thiriart C., Smit L., Bruck C., Gibbs C. J. Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees. Vaccine. 1988 Jun;6(3):229–232. doi: 10.1016/0264-410x(88)90216-2. [DOI] [PubMed] [Google Scholar]
  15. Guyader M., Emerman M., Sonigo P., Clavel F., Montagnier L., Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987 Apr 16;326(6114):662–669. doi: 10.1038/326662a0. [DOI] [PubMed] [Google Scholar]
  16. Hahn B. H., Kong L. I., Lee S. W., Kumar P., Taylor M. E., Arya S. K., Shaw G. M. Relation of HTLV-4 to simian and human immunodeficiency-associated viruses. Nature. 1987 Nov 12;330(6144):184–186. doi: 10.1038/330184a0. [DOI] [PubMed] [Google Scholar]
  17. Kanki P. J., Barin F., M'Boup S., Allan J. S., Romet-Lemonne J. L., Marlink R., McLane M. F., Lee T. H., Arbeille B., Denis F. New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM). Science. 1986 Apr 11;232(4747):238–243. doi: 10.1126/science.3006256. [DOI] [PubMed] [Google Scholar]
  18. Langlois A. J., Matthews T. J., Weinhold K. J., Bolognesi D. P. Immunologic control of a retrovirus-associated murine adenocarcinoma. VII. Tumor cell destruction by macrophages and IgG2A. J Natl Cancer Inst. 1985 Oct;75(4):709–715. [PubMed] [Google Scholar]
  19. Langlois A. J., Matthews T., Roloson G. J., Thiel H. J., Collins J. J., Bolognesi D. P. Immunologic control of the ascites form of murine adenocarcinoma 755. V. Antibody-directed macrophages mediate tumor cell destruction. J Immunol. 1981 Jun;126(6):2337–2341. [PubMed] [Google Scholar]
  20. Levy J. A., Hoffman A. D., Kramer S. M., Landis J. A., Shimabukuro J. M., Oshiro L. S. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science. 1984 Aug 24;225(4664):840–842. doi: 10.1126/science.6206563. [DOI] [PubMed] [Google Scholar]
  21. Ljunggren K., Böttiger B., Biberfeld G., Karlson A., Fenyö E. M., Jondal M. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol. 1987 Oct 1;139(7):2263–2267. [PubMed] [Google Scholar]
  22. Ljunggren K., Chiodi F., Biberfeld G., Norrby E., Jondal M., Fenyö E. M. Lack of cross-reaction in antibody-dependent cellular cytotoxicity between human immunodeficiency virus (HIV) and HIV-related West African strains. J Immunol. 1988 Jan 15;140(2):602–605. [PubMed] [Google Scholar]
  23. Ljunggren K., Fenyö E. M., Biberfeld G., Jondal M. Detection of antibodies which mediate human immunodeficiency virus-specific cellular cytotoxicity (ADCC) in vitro. J Immunol Methods. 1987 Nov 23;104(1-2):7–14. doi: 10.1016/0022-1759(87)90481-9. [DOI] [PubMed] [Google Scholar]
  24. Ljunggren K., Karlson A., Fenyö E. M., Jondal M. Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection. Clin Exp Immunol. 1989 Feb;75(2):184–189. [PMC free article] [PubMed] [Google Scholar]
  25. Lyerly H. K., Matthews T. J., Langlois A. J., Bolognesi D. P., Weinhold K. J. Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A. 1987 Jul;84(13):4601–4605. doi: 10.1073/pnas.84.13.4601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lyerly H. K., Reed D. L., Matthews T. J., Langlois A. J., Ahearne P. A., Petteway S. R., Jr, Weinhold K. J. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses. 1987;3(4):409–422. doi: 10.1089/aid.1987.3.409. [DOI] [PubMed] [Google Scholar]
  27. MOELLER E. CONTACT-INDUCED CYTOTOXICITY BY LYMPHOID CELLS CONTAINING FOREIGN ISOANTIGENS. Science. 1965 Feb 19;147(3660):873–879. doi: 10.1126/science.147.3660.873. [DOI] [PubMed] [Google Scholar]
  28. Matthews T. J., Collins J. J., Roloson G. J., Thiel H. J., Bolognesi D. P. Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum. J Immunol. 1981 Jun;126(6):2332–2336. [PubMed] [Google Scholar]
  29. Merrill J. E., Ullberg M., Jondal M. Influence of IgG and IgM receptor triggering on human natural killer cell cytotoxicity measured on the level of the single effector cell. Eur J Immunol. 1981 Jul;11(7):536–541. doi: 10.1002/eji.1830110703. [DOI] [PubMed] [Google Scholar]
  30. Ojo-Amaize E. A., Nishanian P., Keith D. E., Jr, Houghton R. L., Heitjan D. F., Fahey J. L., Giorgi J. V. Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells. J Immunol. 1987 Oct 1;139(7):2458–2463. [PubMed] [Google Scholar]
  31. Popovic M., Sarngadharan M. G., Read E., Gallo R. C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984 May 4;224(4648):497–500. doi: 10.1126/science.6200935. [DOI] [PubMed] [Google Scholar]
  32. Rook A. H., Lane H. C., Folks T., McCoy S., Alter H., Fauci A. S. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol. 1987 Feb 15;138(4):1064–1067. [PubMed] [Google Scholar]
  33. Starcich B. R., Hahn B. H., Shaw G. M., McNeely P. D., Modrow S., Wolf H., Parks E. S., Parks W. P., Josephs S. F., Gallo R. C. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell. 1986 Jun 6;45(5):637–648. doi: 10.1016/0092-8674(86)90778-6. [DOI] [PubMed] [Google Scholar]
  34. Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 1976 May 15;17(5):565–577. doi: 10.1002/ijc.2910170504. [DOI] [PubMed] [Google Scholar]
  35. Weinhold K. J., Bolognesi D. P., Matthews T. J. Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors. J Natl Cancer Inst. 1985 Oct;75(4):717–724. [PubMed] [Google Scholar]
  36. Weiss R. A., Clapham P. R., Weber J. N., Dalgleish A. G., Lasky L. A., Berman P. W. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 1986 Dec 11;324(6097):572–575. doi: 10.1038/324572a0. [DOI] [PubMed] [Google Scholar]
  37. Weiss R. A., Clapham P. R., Weber J. N., Whitby D., Tedder R. S., O'Connor T., Chamaret S., Montagnier L. HIV-2 antisera cross-neutralize HIV-1. AIDS. 1988 Apr;2(2):95–100. doi: 10.1097/00002030-198804000-00004. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES